Caris MI Clarity offers a prognostic test for early-stage breast cancer distant recurrence risk.

{
  "signal_id": "9b5d059a-2d21-4ec8-a73c-e75dbaa7a60f",
  "signal_type": "linkedin-post-company",
  "signal_subtype": "linkedinPost",
  "detected_at": "2026-08-13T09:52:42.913+00:00",
  "company": {
    "name": "Caris Life Sciences",
    "domain": "carislifesciences.com"
  },
  "data": {
    "tags": [
      "Medical Research",
      "Healthcare Technology",
      "Product Launch"
    ],
    "summary": "Caris MI Clarity offers a prognostic test for early-stage breast cancer distant recurrence risk.",
    "post_url": "https://www.linkedin.com/posts/caris-life-sciences_treatment-decisions-in-early-stage-breast-activity-7493400990365188096-ZEdX",
    "num_likes": 26,
    "post_text": "Treatment decisions in early-stage breast cancer are often made without full visibility into late distant recurrence risk. \n\nCaris MI Clarity™ is a multimodal, computational pathology–based prognostic test that provides independent early (0–5 years) and late (5–15 years) distant recurrence risk from a single test at diagnosis. \n\nLearn more about the clinical approach: https://ow.ly/l6Jc50ZvW4x",
    "initiatives": [
      {
        "topic": "providing independent early and late distant recurrence risk assessment",
        "urgency": 0.5
      }
    ],
    "pain_points": [
      {
        "topic": "lack of visibility into late distant recurrence risk for early-stage breast cancer",
        "intensity": 0.7
      }
    ],
    "posted_date": "2026-08-12T20:20:16.761Z",
    "num_comments": 0,
    "technologies_mentioned": [
      {
        "name": "Caris MI Clarity",
        "status": "using"
      }
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/9b5d059a-2d21-4ec8-a73c-e75dbaa7a60f \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"carislifesciences.com","limit":20}'